These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1908119)

  • 21. Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.
    Franchini M
    Blood Transfus; 2010 Oct; 8(4):292-6. PubMed ID: 20967172
    [No Abstract]   [Full Text] [Related]  

  • 22. Recombinant antihemophilic factor.
    Med Lett Drugs Ther; 1993 Jun; 35(898):51-2. PubMed ID: 8497206
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 24. New treatment for hemophilia.
    FDA Consum; 2003; 37(6):5. PubMed ID: 14983810
    [No Abstract]   [Full Text] [Related]  

  • 25. Rapid elimination of a high-titered F VIII inhibitor by high dose recombinant F VIII combined with high dose immunoglobulin infusion.
    Mauz-Korholz C; Korholz D; Gobel U
    Thromb Haemost; 1997 Aug; 78(2):959. PubMed ID: 9268203
    [No Abstract]   [Full Text] [Related]  

  • 26. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.
    Mannucci PM
    Blood Transfus; 2010 Oct; 8(4):288-91. PubMed ID: 20967171
    [No Abstract]   [Full Text] [Related]  

  • 27. World registry on factor VIII inhibitor patients: why?
    Aledort LM
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):7-9. PubMed ID: 8480198
    [No Abstract]   [Full Text] [Related]  

  • 28. Previously untreated patients and recombinant factor VIII concentrate studies.
    Pasi KJ
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S29-32. PubMed ID: 9351534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro factor VIII recovery during the delivery of ultrapure factor VIII concentrate by continuous infusion.
    DiMichele DM; Lasak ME; Miller CH
    Am J Hematol; 1996 Feb; 51(2):99-103. PubMed ID: 8579073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Wilate--the first VWF/FVIII of the second generation--newly introduced in Germany].
    Pharm Unserer Zeit; 2006; 35(1):83. PubMed ID: 16465869
    [No Abstract]   [Full Text] [Related]  

  • 31. Use of plasma exchange in hereditary deficiency of factor V and factor VIII.
    Sallah AS; Angchaisuksiri P; Roberts HR
    Am J Hematol; 1996 Jul; 52(3):229-30. PubMed ID: 8756096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Acquired hemophilia: current status in Japan and immuno-biochemical features of autoantibodies to factor VIII].
    Tanaka I; Shima N
    Rinsho Ketsueki; 2005 Feb; 46(2):91-8. PubMed ID: 16447701
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
    Mannucci PM
    Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New therapeutic products and difficult decisions.
    Schweiger M
    J Public Health Med; 1999 Mar; 21(1):115-6. PubMed ID: 10321869
    [No Abstract]   [Full Text] [Related]  

  • 35. Proceedings of the First International Symposium on Recombinant Factor VIII. August 26, 1989, Tokyo, Japan.
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):1-56. PubMed ID: 1678551
    [No Abstract]   [Full Text] [Related]  

  • 36. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunologic safety of recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Abildgaard CF
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):44. PubMed ID: 1908127
    [No Abstract]   [Full Text] [Related]  

  • 38. The physiologic basis for therapy of classic hemophilia (factor 8 deficiency) and related disorders. Combined clinical staff conference at the National Institutes of Health.
    Ann Intern Med; 1967 Oct; 67(4):856-82. PubMed ID: 5299081
    [No Abstract]   [Full Text] [Related]  

  • 39. A practical guide to the evaluation and treatment of hemophilia.
    Furie B; Limentani SA; Rosenfield CG
    Blood; 1994 Jul; 84(1):3-9. PubMed ID: 8018925
    [No Abstract]   [Full Text] [Related]  

  • 40. [Recombinant factor VIII. An introduction to recombinant DNA technology and the first results published in the replacement treatment of hemophilia A].
    Juárez Giménez JC; Montoro Ronsano JB; Tusell JM
    Med Clin (Barc); 1994 Nov; 103(15):591-5. PubMed ID: 7990527
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.